Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ASH 2022
ASH 2022
45 days later, BioCryst abandons another program, citing stiff competition
45 days later, BioCryst abandons another program, citing stiff competition
Fierce Biotech
Biocryst
ASH 2022
BCX9930
Flag link:
ASH 2022 – pirtobrutinib leads the post-Imbruvica charge
ASH 2022 – pirtobrutinib leads the post-Imbruvica charge
EP Vantage
ASH 2022
Eli Lilly
BeiGene
Nurix Therapeutics
Brukinsa
pirtobrutinib
NX-2127
Flag link:
ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options
ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options
Fierce Biotech
Novartis
ASH 2022
CAR-T
T-Charge
Flag link:
ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca
ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca
Fierce Biotech
ASH 2022
Novartis
iptacopan
AstraZeneca
Flag link:
ASH 2022 – Orchard gets a Sanfilippo boost
ASH 2022 – Orchard gets a Sanfilippo boost
EP Vantage
ASH 2022
Orchard Therapeutics
Sanfillipo Syndrome
gene therapies
OTL-201
Flag link:
ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?
ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?
Fierce Pharma
Bristol Myers Squibb
ASH 2022
Abecma
clinical trials
Multiple Myeloma
Flag link:
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
ASH 2022
JNJ
talquetamab
Multiple Myeloma
Argenx
Bluebird Bio
Vyvgart
ITP
Flag link:
ASH: Eli Lilly pads novel BTK's case amid FDA review. But AbbVie-J&J, BeiGene and AZ need not worry
ASH: Eli Lilly pads novel BTK's case amid FDA review. But AbbVie-J&J, BeiGene and AZ need not worry
Fierce Biotech
Eli Lilly
ASH 2022
pirtobrutinib
Flag link:
Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma
Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma
Endpoints
Seagen
Adcetris
ASH 2022
Hodgkin's lymphoma
Flag link:
ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets
ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets
Fierce Biotech
ASH 2022
Gracell
CAR-T
Multiple Myeloma
Bristol Myers Squibb
Pfizer
Flag link:
ASH: Roche records phase 3 rare disease win ahead of Soliris showdown
ASH: Roche records phase 3 rare disease win ahead of Soliris showdown
Fierce Biotech
ASH 2022
Roche
PNH
crovalimab
AstraZeneca
Soliris
Flag link:
GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision
GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision
Fierce Biotech
GSK
Sierra Oncology
momelotinib
myelofibrosis
ASH 2022
Flag link:
ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle
ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle
Fierce Pharma
Roche
ASH 2022
AbbVie
Regeneron
lymphoma
Lunsumio
glofitamab
Flag link:
ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead
ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead
Fierce Pharma
Bristol Myers Squibb
Breyanzi
B-cell lymphoma
CAR-T
ASH 2022
Flag link:
ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track
ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track
Fierce Pharma
Bluebird Bio
ASH 2022
Zynteglo
sickle cell disease
gene therapy
lovo-cel
Flag link:
ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease
ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease
Fierce Pharma
ASH 2022
ITP
efgartigimod
Argenx
Flag link:
Setting the Stage for ASH 2022
Setting the Stage for ASH 2022
BioSpace
ASH 2022
AstraZeneca
Janssen
Merck
Vega Therapeutics
Flag link:
ASH preview – waiting for Editas
ASH preview – waiting for Editas
EP Vantage
ASH 2022
sickle cell disease
Bluebird Bio
Sangamo BioSciences
Novartis
Editas Medicine
gene therapy
Vertex Pharmaceuticals
Sanofi
Flag link:
Ash 2022 preview – Affimed and Aptose score
Ash 2022 preview – Affimed and Aptose score
EP Vantage
ASH 2022
Affimed
Aptose Biosciences
ADI-001
CAR-T
AFM13
Flag link:
Ash 2022 preview – a new multiple myeloma mechanism makes a splash
Ash 2022 preview – a new multiple myeloma mechanism makes a splash
EP Vantage
ASH 2022
JNJ
talquetamab
mutliple myeloma
Flag link: